Search results
Showing 1321 to 1335 of 1830 results for carers
disability and can have a considerable impact on them and their family members or carers. It is also a common reason for hospital or...
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
governance leads in their NHS trusts. Ensure that patients and their carers understand the procedure's safety and efficacy, as well as...
of life for people with learning disabilities who have autism and their carers, as well as reducing costs to the NHS.Randomised...
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development Reference number: GID-TA11228 Expected publication date: TBC
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS165Show all sections
Sections for QS165
- Quality statements
- Quality statement 1: Assessment of looked-after children and young people
- Quality statement 2: Assessment of care leavers
- Quality statement 3: Assessment of children and young people in contact with youth offending services
- Quality statement 4: Information and advice for adults
- Update information
- About this quality standard
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard